Table 5.

Failure rates of the studies in support of a short post-travel regimen.

Author	Study size	Efficacy	Failures
Deye et al., 2012 [42]	6 subjects received AP 250/100 mg on d-1 4 subjects received AP 250/100 mg on d + 4	Subjects receiving AP 250/100 mg on d-1 and AP 250/100 mg on d+4 were 100% protected.	0
Shapiro et al., 1999 [11]	6 subjects received 250 mg atovaquone	250 mg of atovaquone protected all subjects	0
Lachish et al., 2016 [43]	33 subjects received AP twice weekly	Malaria incidence in AP group was 0/391 person-months	0
Leshem et al., 2014 [20]	421 subjects used a short-course of AP prophylaxis	None of the subjects reported malaria infection.	0
Petersen et al., 2003 [44]	184 subjects filled in the questionnaires, of which only the 63 subjects of the 1/4 group are included in the total amount of subjects.	44 subjects were total compliant, 37 took 3/4 pills, 29 took 2/4 pills, and 63 took 1/4 pills or fewer. 11 took none at all. No cases of falciparum malaria were recorded.	0 falciparum malaria cases during 6 months, but 1 subject developed P. ovale malaria 4 months after return
Edstein et al., 2005 [12]	–	–	–
Polhemus et al., 2008 [45]	–	–	–
Shanks et al., 1999 [46]	–	–	–
Butcher et al., 2003 [47]	–	–	–
Butcher et al., 2000 [49]	–	–	–
Enosse et al., 2000 [48]	–	–	–
	Total subjects: 533		Total failures: 0 cases excluding ovale malaria cases

AP, atovaquone-proguanil.